Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods and products for treatment of diseases

a technology for diseases and products, applied in the field of steroid treatment, can solve the problems of reducing vision, spots or floaters, affecting the function of the retina, so as to avoid systemic side effects and be simple to administer to the eye

Inactive Publication Date: 2011-07-14
AMPIO PHARMA
View PDF67 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0009]The invention further provides a pharmaceutical product suitable for treatment of the eye. The product comprises a steroid of formula I, IV or V or a pharmacologically-acceptable salt or ester thereof. Treatment of the eye avoids systemic side effects. Particularly preferred are topical pharmaceutical compositions because they are simple to administer to the eye.

Problems solved by technology

In this stage, circulation problems cause areas of the retina to become oxygen-deprived or ischemic.
Unfortunately, these delicate vessels hemorrhage easily, and blood may leak into the retina and vitreous, causing spots or floaters, along with decreased vision.
In the later phases of the disease, continued abnormal vessel growth and scar tissue may cause serious problems, such as retinal detachment and glaucoma.
Age-related macular degeneration is the leading cause of severe vision loss in people age sixty and older.
Therapies that are effective for other tumors currently have serious limitations as brain tumor treatments.
The blood brain barrier may create a particular obstacle to the effective use of chemotherapy in the treatment of brain tumors.
However, most of these treatments have not been successful, and there remains a need for additional treatments for these diseases.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and products for treatment of diseases
  • Methods and products for treatment of diseases
  • Methods and products for treatment of diseases

Examples

Experimental program
Comparison scheme
Effect test

example 1

Trilostane III Effect on HUVEC Angiogenesis: Invasion Chamber

Purpose:

[0179]To examine the effect of trilostane III on fetal calf serum induced endothelial cells invasion through matrigel treated inserts.

Materials:

[0180]Passage 5 Human umbilical vein endothelial cells 7016 (HUVEC), Cambrex (Walkersville, Md.)

[0181]EGM-2 medium, Cambrex (Walkersville, Md.), supplemented to include 0.1% or 5% fetal calf serum

[0182]10 mM LY294002 and LY303511 in DMSO, CalBiochem

[0183]50 mM trilostane III in ethanol, Bowman Research, Newport, South Wales, UK (prepared as, for example, described in GB 1,123,770)

[0184]4 mM Calcein AM in DMSO, Sigma (St. Louis, Mo.)

[0185]Hepes buffered saline solution (HBSS), Cambrex (Walkersville, Md.)

[0186]BD Biocoat Marigel Invasion Chamber, BD Biosciences (San Jose, Calif.)

[0187]microplate fluorescence reader

Protocol: In Short

[0188]1. Trypsinized HUVEC cells from flasks grown in Cambrex EGM-2 media to 70-80% confluence were washed two times with 37° C. EGM-2 with 0.1% F...

example 2

Trilostane III Effect on HUVEC Cell Proliferation

Purpose:

[0191]To determine the effect trilostane III has on HUVEC cell proliferation.

Materials:

[0192]Passage 2 Human umbilical vein endothelial cells (HUVEC), Cambrex

[0193]EGM-2 medium supplemented to include 0.1% and 5% fetal calf serum, Cambrex

[0194]50 mM trilostane III in ethanol, Bowman Research, Newport, South Wales, UK (prepared as, for example, described in GB 1,123,770)

[0195]Hepes buffered saline solution (HBSS), Cambrex

[0196]Celltiter 96 Aqueous One reagent, Promega

[0197]Falcon 96 well tissue culture plates

[0198]Microplate fluorescence reader

Protocol:

[0199]1. HUVEC cells were plated in 96 well plates at 5,000 cells / cm2 and incubated for 24 hours at 37° C. and 5% CO2 in EGM-2 media.

2. Medium was aspirated and the cells were then washed two times with 37° C. HBSS.

3. EGM-2 containing 5% FCS with and without the compound (0.01 μM-200 μM trilostane III) was added to the wells and incubated for 24, 48, or 72 hours.

4. Cells were aga...

example 3

Trilostane III Effect on HUVEC Angiogenesis: Tube formation

Purpose:

[0202]To examine the effect of trilostane III on the formation of tube-like structures by HUVEC cells in an extracellular matrix gel.

Materials:

[0203]Passage 3 Human umbilical vein endothelial cells (HUVEC), Cambrex

[0204]EGM-2 medium, Cambrex: supplemented to include 0.1% or 5% fetal calf serum

[0205]10 mM LY294002 and LY303511 in DMSO, CalBiochem

[0206]50 mM trilostane III in ethanol, Bowman Research, Newport, South Wales, UK (prepared as, for example, described in GB 1,123,770)

[0207]BD Biocoat Angiogenesis system: tube formation assay, BD Biosciences

[0208]Microscope with camera

Protocol: In Short

[0209]1. Trypsinized HUVEC cells from flasks grown in Cambrex EGM-2 media to 70-80% confluence were washed two times with 37° C. EGM-2 with 0.1% FCS.

2. Cell suspensions containing 10,000 cells and compounds in both EGM-2 0.1% and 5% FCS were added per well then incubated for 18 hours at 37° C. and 5% CO2.

3. Following incubation...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
total volumeaaaaaaaaaa
compositionaaaaaaaaaa
pHaaaaaaaaaa
Login to View More

Abstract

The present invention relates to the treatment of diseases and conditions with an effective amount of a steroid having those formulas given in the specification, or a pharmacologically-acceptable salt or ester thereof. The disease or conditions treatable according to the invention include angiogenic diseases and conditions of the eye, angiogenic diseases and conditions of the brain, inflammatory diseases and conditions of the eye, inflammatory diseases and conditions of the brain and neurodegenerative diseases.

Description

REFERENCE TO RELATED APPLICATIONS[0001]This application claims benefit of provisional application No. 60 / 698,723, filed Jul. 12, 2005, provisional application No. 60 / 711,157, filed Aug. 24, 2005, and provisional application 60 / 711,158, filed Aug. 24, 2005. The disclosures of all of the foregoing provisional applications are incorporated herein in their entireties.FIELD OF THE INVENTION[0002]The present invention relates to the treatment of diseases and conditions with an effective amount of a steroid having those formulas given below, or a pharmacologically-acceptable salt or ester thereof. The disease or conditions treatable according to the invention include angiogenic diseases and conditions of the eye or brain, inflammatory diseases and conditions of the eye or brain, and neurodegenerative diseases.BACKGROUND[0003]Over time, diabetes affects the circulatory system of the retina causing diabetic retinopathy, which occurs in about forty percent of diabetics. The earliest phase of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K9/00C07J71/00A61K31/58A61P27/02
CPCA61K31/56A61K31/58A61L2300/604A61L2300/41A61L27/54A61P9/00A61P19/02A61P19/04A61P21/00A61P25/00A61P25/14A61P25/16A61P25/28A61P27/00A61P27/02A61P27/06A61P29/00A61P35/00A61P35/04A61P37/08
Inventor BAR-OR, DAVID
Owner AMPIO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com